Graceptor (GCT) is a new formulation of tacrolimus (TRL), allows once-daily administration while showing similar efficacy and safety to the conventional Prograf (PGF), which is prescribed twice daily. Furthermore, it is not known whether there are any pharmacokinetic differences between once- versus twice daily tacrolimus. Our study sought to compare short-term therapeutic drug monitoring (TDM) of GCT and PGF in de novo kidney transplants.
(PATIENTS AND METHODS)
Fourty de novo kidney transplant recipients were treated with once-daily or twice-daily tacrolimus, TRL and standard immunosuppresive induction therapy. This study compared the pharmacokinetics of tacrolimus
Group1: 20 recipients were treated once-daily formulations of tacrolimus (Graceptor (GCT) ). A target trough is 8-10 ng/ml at 1month
Group2: 20 recipients were treated once-daily formulations of tacrolimus (Prograf (PGF)) A target trough is 10-12 ng/ml at 1month
1,Patient (100%versus 100%) and graft survival (100% versus 100%) at 1year were no different between the groups. Patients of GCT experienced not significantly less CNI toxicity (10% versus 25%, P=0.061) than those in PGF. However, there were significantly less than those in PGF at CMV infection (25% versus 45%, P=0.061).
To cite this abstract in AMA style:Nakagawa Y, Saito K, Ikeda M, Tasaki M, Takahashi K. Clinical Pharmacokinetics of Once-Daily Prolonged-Release Tacrolimus (Graceptor) in De Novo Kidney Transplantation [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/clinical-pharmacokinetics-of-once-daily-prolonged-release-tacrolimus-graceptor-in-de-novo-kidney-transplantation/. Accessed July 24, 2021.
« Back to 2013 American Transplant Congress